www.BuyersGuideChem.com - the directory of chemicals and chemical suppliers. The search engine opens a large data base and offers new supply sources
Welcome About BGC Terms of Use MSDS Banner Adverts Statistics Impressum Sitemap
BGC > Product Search > Gilteritinib | 1254053-43-4
english deutsch español

Suppliers for CAS

1254053-43-4



 

Properties

CAS   1254053-43-4 
Formula   C29H44N8O3 

Structure

4 Registered suppliers


Leap Chem Co., Ltd P.R.China
Aea.ltd P.R.China
Molecular Formula: C29H44N8O3
Molecular Weight: 552.73
BOC Sciences USA
Chemtour Biotech Co., Ltd P.R.China
Description :
Gilteritinib, also known as (ASP2215, is a potent FLT3/AXL inhibitor, which showed potent antileukemic activity against AML with either or both FLT3-ITD and FLT3-D835 mutations. In invitro, among the 78 tyrosine kinases tested, ASP2215 inhibited FLT3, LTK, ALK, and AXL kinases by over 50% at 1 nM with an IC50 value of 0.29 nM for FLT3, approximately 800-fold more potent than for c-KIT, the inhibition of which is linked to a potential risk of myelosuppression. ASP2215 inhibited the growth of MV4-11 cells, which harbor FLT3-ITD, with an IC50 value of 0.92 nM, accompanied with inhibition of pFLT3, pAKT, pSTAT5, pERK, and pS6. ASP2215 decreased tumor burden in bone marrow and prolonged the survival of mice intravenously transplanted with MV4-11 cells. ASP2215 may have potential use in treating AML.
  • Molecular Weight :552.724
Molecular Formula :
C29H44N8O3
Canonical SMILES :
CCC1=NC(=C(N=C1NC2CCOCC2)NC3=CC(=C(C=C3)N4CCC(CC4)N5CCN(CC5)C)OC)C(=O)N
InChI :
InChI=1S/C29H44N8O3/c1-4-23-28(31-20-9-17-40-18-10-20)34-29(26(33-23)27(30)38)32-21-5-6-24(25(19-21)39-3)37-11-7-22(8-12-37)36-15-13-35(2)14-16-36/h5-6,19-20,22H,4,7-18H2,1-3H3,(H2,30,38)(H2,31,32,34)
InChIKey :
GYQYAJJFPNQOOW-UHFFFAOYSA-N
Appearance :
Solid powder
Synonyms :
Gilteritinib; ASP2215; ASP-2215; ASP 2215.
More details are to be found here

Detailed information on the suppliers of Gilteritinib

Properties:

... more properties and specification on Gilteritinib
© Copyright 1996 to 2024 by Netvertise GmbH. All rights reserved